US Patent IssuedNew Zealand Pharmaceuticals Ltd is pleased to announce that the U.S. patent 8,420,063,…
Application of N-acetylmannosamineThe application of N-acetylmannosamine to the mammalian cell culture production of…
NZP is certified ISO 14001New Zealand Pharmaceuticals Ltd is proud to announce that is has been audited by TELARC…
|
The application of N-acetylmannosamine to the mammalian cell culture production of recombinant human glycoproteins
Selwyn C Yorke
Keywords: N-acetylmannosamine, sialylation, glycoproteins.
This mini-review covers recent developments in the understanding, role and value of N-acetylmannosamine (ManNAc) as a compound that can improve sialylation during the production of recombinant human glycoproteins.
Read the review here: The application of N-acetylmannosamine to the mammalian cell culture production of recombinant human glycoproteins.
NZP produces of a range of bulk pharmaceutical intermediates and pharmaceutical ingredients for supply to pharmaceutical and biotechnology companies worldwide.
These bile acids have gained popularity with assistance to solubilise non-polar drugs for delivery in aqueous media by injection.
NZP manufactures several refined bile products that are used as selective inhibitory agents in bacteriological media. These include pure sodium salts of bile acids, which are supplied to biotech and media companies worldwide.
NZP’s sister company, Dextra located in Reading, UK, undertakes custom carbohydrate synthesis and offers a catalogue of carbohydrate derivatives for glycobiology and other applications.
NZP manufactures a range of dietary supplement ingredients under GMP conditions.
In consultation with the aquaculture industry, NZP has developed Mixed Bile Acids, which is easily incorporated into feeds.